SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following segments: Walmart U.S., Walmart International, and Sam's Club U.S. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club U.S. segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is trending as investors react to a quarterly guidance miss and concerns over the health of the U.S. consumer, leading to high retail sentiment and heavy discussion regarding whether the current stock pullback represents an oversold buying opportunity.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull is seeing intense bullish momentum and high retail engagement following a massive second-quarter earnings beat and the successful removal of the Pattern Day Trader rule, which investors believe is driving significant volume and institutional appeal. Community sentiment is overwhelmingly bullish, with many traders discussing a potential short squeeze and viewing the current price action as a long-awaited breakout toward higher valuation targets.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRP is rallying alongside broader crypto market momentum, fueled by investor optimism surrounding a high-profile White House meeting involving Ripple's CEO and key digital asset policy discussions. The community is actively debating whether this movement represents a sustainable trend driven by institutional utility or a temporary pump that retail traders should approach with caution.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group Inc. is trending as investors digest a new bullish initiation from Compass Point with a $44 price target, while active discussions center on the company's significant short interest and the anticipation surrounding its upcoming second-quarter financial results. Community members are closely monitoring for an official earnings date announcement, with many expressing confidence that the combination of strong institutional backing and growth in its AI-focused commercial pipeline could catalyze a major revaluation.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is experiencing significant market interest as investors link the company's recent strategic acquisition of Personalis to Merck and Moderna's successful late-stage cancer vaccine trial. The community is actively discussing the potential for a short squeeze, given the high short interest, while debating the long-term strategic value of the Personalis platform in precision medicine.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is gaining investor attention as market sentiment shifts following positive oncology data from major pharmaceutical players, which analysts believe validates the broader cancer vaccine sector and supports the outlook for the company's own Phase 3 REGAL trial. The community is actively discussing the stock's potential for a significant revaluation ahead of upcoming trial readouts, with many traders focusing on the stock's high short interest and the possibility of a major partnership or acquisition.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna shares are facing extreme volatility and intense retail debate as the market digests the company's recent cancer vaccine breakthrough, with traders clashing over whether the move is a historic opportunity or a classic pump-and-dump setup. Community members are fiercely divided, with some betting on a continued short squeeze toward new highs while others warn of a sharp correction following the record-setting rally.

Deere & Co. engages in the manufacture and distribution of equipment used in agriculture, construction, forestry, and turf care. It operates through the following segments: Agriculture and Turf, Construction and Forestry, and Financial Services. The Agriculture and Turf segment focuses on the distribution and manufacture of a full line of agriculture and turf equipment and related service parts. The Construction and Forestry segment offers machines and service parts used in construction, earthmoving, road building, material handling and timber harvesting. The Financial Services segment finances sales and leases by John Deere dealers of new and used agriculture and turf equipment and construction and forestry equipment. The company was founded by John Deere in 1837 and is headquartered in Moline, IL.

Deere & Co.

Deere & Co

Deere & Co. is trending as investors digest a Q3 earnings beat that showcased resilience through strong construction demand, helping offset ongoing weakness in the agricultural equipment sector. While the stock has seen significant buying momentum and bullish sentiment surrounding its guidance and sector-wide cycle bottom, community discussions remain divided between those betting on an all-time high breakout and those cautious of potential valuation risks.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance is rallying as positive clinical data from Moderna and Merck highlights the potential for personalized immunotherapy, with investors positioning for upcoming revenue guidance updates and pivotal lung cancer trial readouts. The community is actively discussing the stock's de-risking, persistent short interest, and its long-term potential as a standalone TIL therapy leader in the oncology space.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is facing significant market volatility following a guidance cut due to European macroeconomic headwinds, leading investors to scrutinize the firm's growth trajectory and recent executive departures. Despite these concerns, the community remains divided, with bulls highlighting the company's profitability and expanding US presence as signs of long-term value, while others are focusing on the stock's recent sharp decline and technical instability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$CYDY BULLISH!!! HAVE A GREAT WEEKEND LONGS!!! EXCITING TIMES AHEAD!!! HEAR IS PART 1 OF DR. JAY&#39;S LATEST INTERVIEW!!! REST OF IT WILL BE IN MY COMMENTS!!! ALL IN TO WIN!!! ALL IN TO SAVE LIVES!!!  
Guest today is Dr. Jay Lalezari, CEO of CytoDyn, cytodyn.com. And Jay, I want to 
welcome you to the show. I appreciate you taking a few minutes to be with us. 
Jay Lalezari: Thank you, Karen. It&#39;s a pleasure to join you. 
Karen Jagoda: Thank you. We wanted to talk today about triple-negative breast cancer. So tell 
us why the company has decided to focus on that condition. Jay Lalezari: When I became CEO back in November of 2023, my first order of business was 
to figure out where CytoDyn should go with this intriguing monoclonal antibody 
called leronlimab that targets CCR5. And we looked at a number of indications, 
and by far and away, the data that we found in solid tumor oncology is clearly 
the place CytoDyn will go to create the most benefit for patients.....

Todd Langevin

Brian

CJ Sigler

Tuna T

Thomas Migliara

Rich F

Robert

Stuttgart Mercedes

Thor

Maggie16

Doug Chase

LIVIMMUNE Bound

Scott Bowers

Thomas H Butcher

Tom Wright

Joe Blow

Derek White

S. T.

anh vo

Paul Steele

Dustin

Ryan Morrison

vivamiga

Scott

christopher

Timothy OConnor

Gailgooglie

Charles

CytoDyn is a biotechnology company focused on developing innovative treatments for multiple therapeutic indications based on Leronlimab (PRO 140).

CytoDyn Inc.

StockTwits Web

CytoDyn Inc

 BULLISH!!! HAVE A GREAT WEEKEND LONGS!!! EXCITING TIMES AHEAD!!! HEAR IS PART 1 OF DR. JAY'S LATEST INTERVIEW!!! REST OF IT WILL BE IN MY COMMENTS!!! ALL IN TO WIN!!! ALL IN TO SAVE LIVES!!!  
Guest today is Dr. Jay Lalezari, CEO of CytoDyn, 

. And Jay, I want to 
welcome you to the show. I appreciate you taking a few minutes to be with us. 
Jay Lalezari: Thank you, Karen. It's a pleasure to join you. 
Karen Jagoda: Thank you. We wanted to talk today about triple-negative breast cancer. So tell 
us why the company has decided to focus on that condition. Jay Lalezari: When I became CEO back in November of 2023, my first order of business was 
to figure out where CytoDyn should go with this intriguing monoclonal antibody 
called leronlimab that targets CCR5. And we looked at a number of indications, 
and by far and away, the data that we found in solid tumor oncology is clearly 
the place CytoDyn will go to create the most benefit for patients.....

Steven feldman

$CYDY BULLISH PART 2 and the most 
benefit for our shareholders. We recently presented some data in triple- 
negative breast cancer that is truly remarkable and potentially paradigm-shifting 
in the world of solid tumor oncology. 
Karen Jagoda: So, say more about what you mean by paradigm shifting, because solid tumors 
have been attacked fairly successfully, but you&#39;re taking it to the next level. 
Jay Lalezari: Yeah. There are a number of solid tumors, triple negative breast cancer among 
them, where we still struggle to find effective therapies, in part because, by 
virtue of being triple negative, there aren&#39;t a lot of good targets on the cancer. 
And some years ago, CytoDyn launched three clinical studies in oncology 
focusing on women with triple-negative breast cancer. And those studies ran for 
a couple of years, they were then shut down, and there was a period of time 
where patients were lost to follow-up.

 BULLISH PART 2 and the most 
benefit for our shareholders. We recently presented some data in triple- 
negative breast cancer that is truly remarkable and potentially paradigm-shifting 
in the world of solid tumor oncology. 
Karen Jagoda: So, say more about what you mean by paradigm shifting, because solid tumors 
have been attacked fairly successfully, but you're taking it to the next level. 
Jay Lalezari: Yeah. There are a number of solid tumors, triple negative breast cancer among 
them, where we still struggle to find effective therapies, in part because, by 
virtue of being triple negative, there aren't a lot of good targets on the cancer. 
And some years ago, CytoDyn launched three clinical studies in oncology 
focusing on women with triple-negative breast cancer. And those studies ran for 
a couple of years, they were then shut down, and there was a period of time 
where patients were lost to follow-up.

$CYDY BULLISH!!! PART 3 Jay Lalezari: We have now been able to follow up on the 28 women who were enrolled in 
that study and have found that five of them are alive today, about five plus 
years later, three of whom have no evidence of disease. And these are women 
who were fourth-line median, fourth-line treatment median of two previous 
lines of treatment in the metastatic setting. 60% had organ metastasis, 30% had 
brain metastasis. The median survival of a population like that is generally 
measured in weeks or months. And the fact that we have five out of 28 who are 
alive and doing well in what appears to be a sustained remission five years later 
is absolutely remarkable. It is retrospective, but it is remarkable nonetheless. 
Karen Jagoda: Tell us a little bit about the CCR5 receptor, which is part of this story, and why 
has that been an unexplored target in the past? 
An Empowered Patient Podcast Published November 14, 2025

 BULLISH!!! PART 3 Jay Lalezari: We have now been able to follow up on the 28 women who were enrolled in 
that study and have found that five of them are alive today, about five plus 
years later, three of whom have no evidence of disease. And these are women 
who were fourth-line median, fourth-line treatment median of two previous 
lines of treatment in the metastatic setting. 60% had organ metastasis, 30% had 
brain metastasis. The median survival of a population like that is generally 
measured in weeks or months. And the fact that we have five out of 28 who are 
alive and doing well in what appears to be a sustained remission five years later 
is absolutely remarkable. It is retrospective, but it is remarkable nonetheless. 
Karen Jagoda: Tell us a little bit about the CCR5 receptor, which is part of this story, and why 
has that been an unexplored target in the past? 
An Empowered Patient Podcast Published November 14, 2025

$CYDY BULLISH!!! PART 5 Jay Lalezari: Well, CCR5 emerged in the context of HIV, where it was found to be a secondary 
co-receptor for HIV entry. And for years, the development of leronlimab was 
focused on its potential role in the treatment of HIV. And indeed, leronlimab 
works as an antiviral. And over the years, leronlimab, I would add, has been 
given to almost 1600 patients, and we do not see a dominant safety signal or 
concern, which is just not something you can say about another cancer 
candidate therapeutic. 
Jay Lalezari: Over the years, it became clear that CCR5 was not just for the virus to get inside 
the cell, but was playing a key role in setting up the tumor microenvironment in 
a variety of solid tumors that were CCR5 positive. That included typically triple- 
negative breast cancer, colon cancer, prostate cancer, pancreatic cancer, 
sarcoma, glioblastoma, and the urothelial cancers in particular.

 BULLISH!!! PART 5 Jay Lalezari: Well, CCR5 emerged in the context of HIV, where it was found to be a secondary 
co-receptor for HIV entry. And for years, the development of leronlimab was 
focused on its potential role in the treatment of HIV. And indeed, leronlimab 
works as an antiviral. And over the years, leronlimab, I would add, has been 
given to almost 1600 patients, and we do not see a dominant safety signal or 
concern, which is just not something you can say about another cancer 
candidate therapeutic. 
Jay Lalezari: Over the years, it became clear that CCR5 was not just for the virus to get inside 
the cell, but was playing a key role in setting up the tumor microenvironment in 
a variety of solid tumors that were CCR5 positive. That included typically triple- 
negative breast cancer, colon cancer, prostate cancer, pancreatic cancer, 
sarcoma, glioblastoma, and the urothelial cancers in particular.

$CYDY BULLISH!!! PART 6 So CCR5 helps 
the cancer set up a tumor microenvironment that helps it both build blood 
vessels to provide nourishment for the cancer and attract suppressor cells that 
keep the host immune system at bay. 
Jay Lalezari: And by blocking that signaling through CCR5 with our antibody with leronlimab, 
we are breaking down that protective, suppressed immune environment and 
allowing the host immune system to now go after the virus. And what we found 
as the common denominator in these five women who received leronlimab was 
that they then had an induction of something called PDL-1 on their circulating 
tumor cells, which is an indication that the tumor has gone from cold to hot or 
from suppressed to inflamed.

 BULLISH!!! PART 6 So CCR5 helps 
the cancer set up a tumor microenvironment that helps it both build blood 
vessels to provide nourishment for the cancer and attract suppressor cells that 
keep the host immune system at bay. 
Jay Lalezari: And by blocking that signaling through CCR5 with our antibody with leronlimab, 
we are breaking down that protective, suppressed immune environment and 
allowing the host immune system to now go after the virus. And what we found 
as the common denominator in these five women who received leronlimab was 
that they then had an induction of something called PDL-1 on their circulating 
tumor cells, which is an indication that the tumor has gone from cold to hot or 
from suppressed to inflamed.

$CYDY BULLISH!!! PART 7  And then these five women were the ones who 
just happened to get an immune class of drugs called immune checkpoint 
inhibitors, PDL-1 or PDL-1 blockers, commonly known as Keytruda. So that was 
the magic formula that seemed to now correlate with their long-term sustained 
remission - that they received leromlimab, they induced PDL-1, they got a 
checkpoint inhibitor, and now they&#39;re alive today despite the long odds given 
their situation five years ago. 
Karen Jagoda: And it&#39;s really significant that what happens is that you turn the tumor from cold 
to hot. So, say a little bit more about the nature of cold tumors and how they&#39;re 
able to evade the immune system.

 BULLISH!!! PART 7  And then these five women were the ones who 
just happened to get an immune class of drugs called immune checkpoint 
inhibitors, PDL-1 or PDL-1 blockers, commonly known as Keytruda. So that was 
the magic formula that seemed to now correlate with their long-term sustained 
remission - that they received leromlimab, they induced PDL-1, they got a 
checkpoint inhibitor, and now they're alive today despite the long odds given 
their situation five years ago. 
Karen Jagoda: And it's really significant that what happens is that you turn the tumor from cold 
to hot. So, say a little bit more about the nature of cold tumors and how they're 
able to evade the immune system.

$CYDY BULLISH!!! PART 8 Jay Lalezari: Yes, that is absolutely correct, and it&#39;s the center of this. When a cancerous solid 
tumor sets out to grow, it has to do two things. It has to build blood vessels that 
specifically provide nourishment so that it can grow beyond a certain size. And 
then the tumor is a foreign antigen that the normally the immune system would 
attack and eliminate. Cancers have a variety of strategies for keeping the immune system at bay. It&#39;s 
just that some solid tumors use the CCR5 receptor on suppressor cells in tissue 
macrophages to recruit those cells to do the cancerous business for it. And so 
that cold tumor environment has blood vessels that feed the cancer, but has a 
collection of suppressor cells, both cells called regulatory T cells, for which the 
Nobel Prize in Medicine was just awarded a couple of weeks ago, and other 
suppressor cells to create a cold tumor environment that the immune system 
doesn&#39;t penetrate very well, if at all.

 BULLISH!!! PART 8 Jay Lalezari: Yes, that is absolutely correct, and it's the center of this. When a cancerous solid 
tumor sets out to grow, it has to do two things. It has to build blood vessels that 
specifically provide nourishment so that it can grow beyond a certain size. And 
then the tumor is a foreign antigen that the normally the immune system would 
attack and eliminate. Cancers have a variety of strategies for keeping the immune system at bay. It's 
just that some solid tumors use the CCR5 receptor on suppressor cells in tissue 
macrophages to recruit those cells to do the cancerous business for it. And so 
that cold tumor environment has blood vessels that feed the cancer, but has a 
collection of suppressor cells, both cells called regulatory T cells, for which the 
Nobel Prize in Medicine was just awarded a couple of weeks ago, and other 
suppressor cells to create a cold tumor environment that the immune system 
doesn't penetrate very well, if at all.

$CYDY BULLISH!!! PART 9 Jay Lalezari: And so that keeps the tumor from being recognized and destroyed. And so 
that&#39;s called a cold tumor microenvironment. And when you can break down 
that microenvironment and allow the cytotoxic T cells to enter the 
microenvironment and generate all these inflammatory cytokines, that&#39;s when tumor environment becomes hot. And one thing a cancer can do in response to 
an invading immune system is to generate this protein called PDL-1. 
Jay Lalezari: What PDL does is bind to an off switch on these attacking immune cells called 
BD-1, and by flipping that off switch, the tumor is able to downregulate or turn 
down or push back on the invading immune system. And so that&#39;s where the 
checkpoint inhibitor, Keytruda, comes in. And that is that the women who 
received leronlimab apparently had a breakdown in the tumor 
microenvironment, then secreted PDL-1 in an effort to repel the immune 
system.

 BULLISH!!! PART 9 Jay Lalezari: And so that keeps the tumor from being recognized and destroyed. And so 
that's called a cold tumor microenvironment. And when you can break down 
that microenvironment and allow the cytotoxic T cells to enter the 
microenvironment and generate all these inflammatory cytokines, that's when tumor environment becomes hot. And one thing a cancer can do in response to 
an invading immune system is to generate this protein called PDL-1. 
Jay Lalezari: What PDL does is bind to an off switch on these attacking immune cells called 
BD-1, and by flipping that off switch, the tumor is able to downregulate or turn 
down or push back on the invading immune system. And so that's where the 
checkpoint inhibitor, Keytruda, comes in. And that is that the women who 
received leronlimab apparently had a breakdown in the tumor 
microenvironment, then secreted PDL-1 in an effort to repel the immune 
system.

$CYDY BULLISH!!! PART 10  The women who just happened to get a checkpoint inhibitor to block 
the action of that protein, PDL-1, they&#39;re the ones who survived. 
Karen Jagoda: And the PDL-1 would not have worked otherwise, in terms of the 
immunotherapies. I mean, those people would be in the category where the 
immunotherapy just didn&#39;t work. Would that be fair to say? 
Jay Lalezari: That&#39;s exactly right. And so immunotherapy has been very successful, 
particularly in the last decade, but it&#39;s been successful in patients with solid 
tumors who express PDL-1. And unfortunately, it&#39;s the majority of solid tumors 
that don&#39;t. So the majority of solid tumors are cold. So for the patients whose 
cancers are PDL-1 positive, immunotherapy is hugely successful. GSK just got a 
breakthrough designation for their PDL-1 inhibitor, where their response rate 
was 100% in patients with rectal cancer who had hot tumors.

 BULLISH!!! PART 10  The women who just happened to get a checkpoint inhibitor to block 
the action of that protein, PDL-1, they're the ones who survived. 
Karen Jagoda: And the PDL-1 would not have worked otherwise, in terms of the 
immunotherapies. I mean, those people would be in the category where the 
immunotherapy just didn't work. Would that be fair to say? 
Jay Lalezari: That's exactly right. And so immunotherapy has been very successful, 
particularly in the last decade, but it's been successful in patients with solid 
tumors who express PDL-1. And unfortunately, it's the majority of solid tumors 
that don't. So the majority of solid tumors are cold. So for the patients whose 
cancers are PDL-1 positive, immunotherapy is hugely successful. GSK just got a 
breakthrough designation for their PDL-1 inhibitor, where their response rate 
was 100% in patients with rectal cancer who had hot tumors.

$CYDY BULLISH!!! PART 11 Jay Lalezari: So if we can cause cold tumors to go hot, we have a treatment that is highly 
successful. The trick is getting those cold tumors to turn hot. And that&#39;s where 
the excitement with leronlimab is that we saw that patients who got one of the 
two higher doses, both of which were well tolerated, 88% of those women had 
their tumors go from cold to hot over a period of one to two months. 
Karen Jagoda: That&#39;s really significant. And would this also be effective for colorectal cancer? 
Jay Lalezari: Yes, indeed. We started, we didn&#39;t know the full PDL-1 story, so we were 
working with the FDA and their requirements for how CytoDyn should move 
forward. And so the first study we designed was in colorectal cancer, looking at 
two doses, but it was all before we knew about the PDL-1 and checkpoint 
inhibitor story.

 BULLISH!!! PART 11 Jay Lalezari: So if we can cause cold tumors to go hot, we have a treatment that is highly 
successful. The trick is getting those cold tumors to turn hot. And that's where 
the excitement with leronlimab is that we saw that patients who got one of the 
two higher doses, both of which were well tolerated, 88% of those women had 
their tumors go from cold to hot over a period of one to two months. 
Karen Jagoda: That's really significant. And would this also be effective for colorectal cancer? 
Jay Lalezari: Yes, indeed. We started, we didn't know the full PDL-1 story, so we were 
working with the FDA and their requirements for how CytoDyn should move 
forward. And so the first study we designed was in colorectal cancer, looking at 
two doses, but it was all before we knew about the PDL-1 and checkpoint 
inhibitor story.

$CYDY BULLISH!!! I THINK I GOT IT ALL!!! THANKS FOR YOUR PATIENCE!!!

Thomas M.

 BULLISH!!! I THINK I GOT IT ALL!!! THANKS FOR YOUR PATIENCE!!!

@u2rocksme Phenomenal postings....THX 10% !!